Janus Henderson Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Janus Henderson Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,051,077	Closed	-$107M	–	2609
2023 Q2	$107M	Buy	1,051,077 +827,758	+371%	+$78.3M	0.07%	248
2023 Q1	$20.3M	Buy	223,319 +217,947	+4,057%	+$12.8M	0.01%	576
2022 Q4	$204K	Buy	+5,372	New	+$185K	﹤0.01%	2177
2021 Q2	–	Sell	-71,876	Closed	-$7.17M	–	1693
2021 Q1	$7.17M	Buy	71,876 +22,285	+45%	+$2.6M	﹤0.01%	951
2020 Q4	$6.13M	Buy	+49,591	New	+$6.52M	﹤0.01%	928

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Janus Henderson Group's RETA Position: Q3 2023 in Review

Janus Henderson Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 1,051,077 shares — an estimated $107M sold.

Janus Henderson Group first reported a position in RETA in Q4 2020 and held it in 5 quarters. The position peaked at $107M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Janus Henderson Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Janus Henderson Group sold 1,051,077 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $107M.
Janus Henderson Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 5 quarters.
Janus Henderson Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $107M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Janus Henderson Group's 13F filing for Q3 2023, filed 14 Nov 2023.